Hydantoin-substituted 4,6-dichloroindole-2-carboxylic acids as ligands with high affinity for the glycine binding site of the NMDA receptor.

A novel series of C-3 substituted 4,6-dichloroindole-2-carboxylic acids was synthesized to investigate the influence of different hydrogen-bond donor and acceptor groups at this specific position on the affinity to the glycine site of the NMDA receptor. These novel 3-indolylmethyl derivatives with ring-open (amines, sulfonamides, amides, ureas) and cyclic substituents (imidazolidin-2-ones, (thio)hydantoins) led to the discovery that compounds bearing a hydantoin substituent at the C-3 position of the indole nucleus are the most promising ones. In this series the hydantoins, ureas, and imidazolidin-2-ones were identified as very potent inhibitors of the binding of the glycine site specific ligand [(3)H]MDL 105,519 to pig cortical brain membranes. Since the hydantoins can be produced via a versatile synthetic approach, further amendments of the hydantoin-substituted compounds were conducted to elucidate the influence of aromatic and aliphatic moieties at position 3 of the hydantoin as well as of sterically hindered compounds (5-substituted hydantoins). On the basis of the pharmacological data obtained in displacement experiments with [(3)H]MDL 105,519 and the emerging structure-activity relationships, we confirm the existing pharmacophore model that suggests a hydrogen-bond acceptor and an aromatic substituent at position 3 of the indole as the key features for high affinity. Log P values indicate brain permeability and selected compounds showed anticonvulsant activity in vivo. Binding studies for the sodium channel (site 2) were also performed on some selected compounds.

[1]  L. Iversen,et al.  The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. , 1994, Journal of medicinal chemistry.

[2]  R. Di Fabio,et al.  Unusual synthesis of new glycine antagonists via sequential aldol condensation-lactonization-elimination reaction. , 1998, Bioorganic & medicinal chemistry letters.

[3]  A. Avdeef,et al.  PH-metric log P 11. pKa determination of water-insoluble drugs in organic solvent-water mixtures. , 1999, Journal of pharmaceutical and biomedical analysis.

[4]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[5]  A. Leo,et al.  Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. , 1987, Journal of pharmaceutical sciences.

[6]  J. Olney,et al.  Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. , 1989, Science.

[7]  J. Hawkinson,et al.  Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines. , 1999, Journal of medicinal chemistry.

[8]  F. Salituro,et al.  3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex. , 1990, Journal of medicinal chemistry.

[9]  W. Löscher,et al.  The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices , 1991, Epilepsy Research.

[10]  J. Massagué TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[11]  G. Höfner,et al.  5‐Arylidene‐3‐aryl‐pyrrolidine‐2,4‐diones with Affinity to the N‐Methyl‐D‐aspartate (Glycine Site) Receptor, Part I , 1998, Archiv der Pharmazie.

[12]  W. Löscher,et al.  The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. I. The influence of administration vehicles , 1990, Epilepsy Research.

[13]  B. Harrison,et al.  [3H]5,7-dichlorokynurenic acid, a novel radioligand labels NMDA receptor-associated glycine binding sites. , 1991, European journal of pharmacology.

[14]  A. Reggiani,et al.  Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia. , 1999, Journal of medicinal chemistry.

[15]  B. D. Harris,et al.  Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures. , 1996 .

[16]  W. Löscher,et al.  New visions in the pharmacology of anticonvulsion. , 1998, European journal of pharmacology.

[17]  G. Höfner,et al.  Characterisation of the binding of [3H]MDL 105,519, a radiolabelled antagonist for the N-methyl-d-aspartate-associated glycine site, to pig cortical brain membranes , 1997, Neuroscience Letters.

[18]  D. Butterfield,et al.  Amyloid β Peptide (25–35) Inhibits Na+‐Dependent Glutamate Uptake in Rat Hippocampal Astrocyte Cultures , 1996, Journal of neurochemistry.

[19]  B. Harrison,et al.  [3H]MDL 105,519, a high-affinity radioligand for the N-methyl-D-aspartate receptor-associated glycine recognition site. , 1996, The Journal of pharmacology and experimental therapeutics.

[20]  G. Dannhardt,et al.  The NMDA receptor complex: a promising target for novel antiepileptic strategies. , 2001, Current medicinal chemistry.

[21]  G. Tarzia (E)‐3‐(2‐(N‐Phenylcarbamoyl)vinyl)pyrrole‐2‐carboxylic Acid Derivatives. A Novel Class of Glycine Site Antagonists. , 1998 .

[22]  B. Meldrum,et al.  Anticonvulsant action of excitatory amino acid antagonists. , 1982, Science.

[23]  A. Capelli,et al.  Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. , 1997, Journal of medicinal chemistry.

[24]  P. Leeson,et al.  4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor. , 1992, Journal of medicinal chemistry.

[25]  B. Meldrum,et al.  Na+ channels as targets for neuroprotective drugs. , 1995, Trends in pharmacological sciences.

[26]  J. Kemp,et al.  4-substituted-3-phenylquinolin-2(1H)-ones: acidic and nonacidic glycine site N-methyl-D-aspartate antagonists with in vivo activity. , 1997, Journal of medicinal chemistry.

[27]  E. Mohr,et al.  Huntington's disease: pathogenesis, diagnosis and treatment. , 1994, Journal of psychiatry & neuroscience : JPN.

[28]  W. Löscher Animal Models of Epilepsy and Epileptic Seizures , 1999 .

[29]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[30]  S. Espitia,et al.  Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines. , 2001, Journal of medicinal chemistry.

[31]  G. Dannhardt,et al.  The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. , 1998, Current medicinal chemistry.

[32]  G. Dannhardt,et al.  Benzimidazoles as NMDA Glycine‐Site Antagonists: Study on the Structural Requirements in 2‐Position of the Ligand , 2000, Archiv der Pharmazie.

[33]  W. Catterall,et al.  Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. , 1981, The Journal of biological chemistry.

[34]  C. Becker,et al.  The inhibitory glycine receptor: prospects for a therapeutic orphan? , 1998, Current pharmaceutical design.

[35]  B. D. Harris,et al.  Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1). , 1996, The Journal of organic chemistry.

[36]  G. Höfner,et al.  Characterisation of [3H]MK-801 binding and its cooperative modulation by pig brain membranes. , 1996, Journal of receptor and signal transduction research.

[37]  C. Arias,et al.  β‐Amyloid peptide fragment 25–35 potentiates the calcium‐dependent release of excitatory amino acids from depolarized hippocampal slices , 1995, Journal of neuroscience research.

[38]  H. White Comparative Anticonvulsant and Mechanistic Profile of the Established and Newer Antiepileptic Drugs , 1999, Epilepsia.

[39]  M. Mattson,et al.  beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  K. Lange,et al.  Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease , 1991, Journal of neural transmission. Parkinson's disease and dementia section.

[41]  W. Löscher,et al.  The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models , 1991, Epilepsy Research.

[42]  A. Ganesan,et al.  Solution-Phase Synthesis of a Combinatorial Thiohydantoin Library(1). , 1997, The Journal of organic chemistry.

[43]  J. Monahan,et al.  Novel indole-2-carboxylates as ligands for the strychnine-insensitive N-methyl-D-aspartate-linked glycine receptor. , 1991, Journal of medicinal chemistry.

[44]  P. Krogsgaard‐Larsen,et al.  Ligands for Glutamate Receptors: Design and Therapeutic Prospects , 2000 .

[45]  P D Leeson,et al.  Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. , 1997, Journal of medicinal chemistry.

[46]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[47]  M. Baudry,et al.  [3H]Dizocilpine Association Kinetics Distinguish Stimulatory and Inhibitory Polyamine Sites of N‐Methyl‐d‐Aspartate Receptors , 1994, Journal of neurochemistry.